DDInter1852 DDInter1729
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Treprostinil {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulindac
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) is bound by {v} (Compound) Sulindac
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Tizanidine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Tizanidine {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamterene
Triamterene {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)
Treprostinil (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulindac (Compound)
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is regulated by AKR1B1 (Gene) and AKR1B1 (Gene) is bound by Sulindac (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is associated with osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Treprostinil may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Treprostinil may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Triamterene and Triamterene (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)